Newly-presented data from the RHEIA trial suggest that transcatheter aortic valve implantation (TAVI) using SAPIEN 3 or SAPIEN 3 Ultra is superior to surgical aortic valve replacement for reducing the rates of death, stroke or rehospitalization in women with severe aortic stenosis.